HOUSTON, Nov. 8, 2018 /PRNewswire/ -- Texan Allergy & Sinus Center (TASC), the largest and fastest-growing allergy company in the state, is expanding its footprint by opening multiple clinics across the greater Houston area. TASC has hired board-certified Houston allergist Dr. Rubina Wahid to spearhead the company's efforts to open six clinics in Houston and surrounding cities, with the first two opening mid-November in Sugar Land and Katy. The company has 30 clinics planned by 2019, with 22 current locations across major cities including Dallas, Austin and San Antonio.
"We're extremely excited to expand our services to the greater Houston area," said Allie Thompson, CEO and co-founder of TASC. "Our partnership with Source Capital has helped us strategically identify and support areas for our company to grow."
TASC offers a unique and effective alternative to conventional allergy treatment known as sublingual immunotherapy, or allergy drops. The treatment is widely popular among allergy sufferers due to its ease and convenience. Patients as young as 6 months old can benefit from the treatment. TASC will also be offering the groundbreaking food allergy treatment oral immunotherapy (OIT) at the Houston clinics along with an array of sinus procedures, including Balloon Sinuplasty. Balloon Sinuplasty is a minimally invasive, in-office procedure that is gaining traction in clinics nationwide. Dr. Chris Thompson, chief medical officer and co-founder of TASC, served on a panel of physicians who helped shape the balloon technology when it was first being designed over 10 years ago.
In August, TASC announced plans to further expand throughout Texas and out-of-state after partnering with Source Capital LLC, a private equity firm. TASC and Source Capital plan to continue building upon the company's market-leading presence across Central Texas, while also targeting expansion opportunities in key Texas and out-of-state markets. TASC will pursue new affiliations with independent allergy practices to continue to support clinicians while maintaining a patient-first culture.
For more information: http://www.texanallergy.com.